

XII Meeting. State of the Art in
HEART FAILURE
CLINICAL PRACTICE AND ORGANIZATIONAL MODELS

Venue: Hotel Meliá María Pita, A Coruña

A Coruña 26-27 September 2025




#ACORUÑAHF2025



Acoramidis, a new TTR stabilizer Antibody-based therapies

Rapidly changing opportunities


Prof. Giuseppe Vergaro || Scuola Superiore Sant'Anna & Fondazione Monasterio, Pisa



Patients remaining at risk (cumulative events)

Continuous tafamidis	176	172	170	164	155	148	144	139	132	128	117	107	104	99	95	91	85	78	72	56	30	17	6	1	0
	(0)	(4)	(6)	(12)	(21)	(28)	(32)	(37)	(44)	(48)	(54)	(56)	(59)	(63)	(66)	(69)	(73)	(74)	(75)	(78)	(78)	(78)	(78)	(79)	(79)
Placebo to tafamidis	177	173	171	163	161	150	141	131	118	113	93	77	70	62	58	54	51	45	36	29	15	8	0	0	0
	(0)	(4)	(6)	(14)	(16)	(27)	(36)	(46)	(59)	(64)	(75)	(81)	(88)	(95)	(99)	(102)	(104)	(106)	(110)	(110)	(110)	(111)	(111)	(111)	(111)


Elliott et al. Circ HF 2022



Patients remaining at risk (cumulative events)

Continuous tafamidis	176	172	170	164	155	148	144	139	132	128	117	107	104	99	95	91	85	78	72	56	30	17	6	1	0
	(0)	(4)	(6)	(12)	(21)	(28)	(32)	(37)	(44)	(48)	(54)	(56)	(59)	(63)	(66)	(69)	(73)	(74)	(75)	(78)	(78)	(78)	(78)	(79)	(79)
Placebo to tafamidis	177	173	171	163	161	150	141	131	118	113	93	77	70	62	58	54	51	45	36	29	15	8	0	0	0
	(0)	(4)	(6)	(14)	(16)	(27)	(36)	(46)	(59)	(64)	(75)	(81)	(88)	(95)	(99)	(102)	(104)	(106)	(110)	(110)	(110)	(111)	(111)	(111)	(111)

Elliott et al. Circ HF 2022



Castiglione V & Vergaro G 2021



Contents lists available at ScienceDirect

European Journal of Internal Medicine

journal homepage: www.elsevier.com/locate/ejim




Original Article

Transthyretin serum levels and clinical outcomes in patients with transthyretin amyloid cardiomyopathy

Annamaria Minervini ^{a,1}, Gonzalo Barge-Caballero ^{b,c,1}, Andrea López-López ^d, Manuel López-Pérez ^e, Eva González-Babarro ^f, Inés Gómez-Otero ^{c,g}, Raquel Bilbao-Quesada ^h, Mario Gutiérrez-Feijoo ⁱ, Alfonso Varela-Román ^{c,g}, Alberto Bouzas-Mosquera ^{b,c}, María G. Crespo-Leiro ^{b,c,j}, Eduardo Barge-Caballero ^{b,c,e}

Serum transthyretin

- 0-20 mg/dl
- 20.1-25 mg/dl
- >25 mg/dl



	N at risk							
	0	1	2	3	4	5	6	7
0-20 mg/dl	75	46	28	18	13	7	2	0
20.1-25 mg/dl	64	45	32	20	16	9	3	0
>25 mg/dl	77	55	39	26	20	15	5	0




INTERDISCIPLINARY CENTER
Sant'Anna
Scuola Universitaria Superiore Pisa



TTR and outcome in treated ATTR-CM patients

All-cause death + HF hospitalization




- TTR ≥ 18.0 mg/dL AND ΔTTR 0-30 ≥ 7.5 mg/dL
- - - TTR ≥ 18.0 mg/dL AND ΔTTR 0-30 < 7.5 mg/dL
OR
TTR < 18.0 mg/dL AND ΔTTR 0-30 ≥ 7.5 mg/dL
- - - TTR < 18.0 mg/dL AND ΔTTR 0-30 < 7.5 mg/dL

Both below cut-off	20	14	9	3
One below cut-off	84	54	43	31
Both above cut-off	46	36	26	16

Castiglione V & Vergaro G submitted

TTR and outcome in treated ATTR-CM patients



All-cause death + HF hospitalization



- TTR ≥ 18.0 mg/dL AND Δ TTR 0-30 ≥ 7.5 mg/dL
- - - OR TTR ≥ 18.0 mg/dL AND Δ TTR 0-30 < 7.5 mg/dL
OR TTR < 18.0 mg/dL AND Δ TTR 0-30 ≥ 7.5 mg/dL
- TTR < 18.0 mg/dL AND Δ TTR 0-30 < 7.5 mg/dL



Both below cut-off	20	14	9	3
One below cut-off	84	54	43	31
Both above cut-off	46	36	26	16

Castiglione V & Vergaro G submitted



Modified from Vergaro et al. 2025


ACORAMIDIS



Acoramidis forms hydrogen bonds with the same serine residues at position 117 that stabilize the T119M variant

Judge DP et al., 2019


ATTRibute-CM – Phase III Study



Acoramidis increases serum TTR levels vs. placebo




Mean change from baseline in sTTR levels in patients receiving acoramidis or placebo through Month 30 (N=557)




Maurer MS et al., 2025

TTR stabilization with acoramidis



In vivo sTTR



Adapted from Ji AX, et al. 2025
Maurer MS, et al. 2025


Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy

J.D. Gillmore, D.P. Judge, F. Cappelli, M. Fontana, P. Garcia-Pavia, S. Gibbs, M. Grogan, M. Hanna, J. Hoffman, A. Masri, M.S. Maurer, J. Nativi-Nicolau, L. Obici, S.H. Poulsen, F. Rockhold, K.B. Shah, P. Soman, J. Garg, K. Chiswell, H. Xu, X. Cao, T. Lystig, U. Sinha, and J.C. Fox, for the ATTRIBUTE-CM Investigators*



INTERDISCIPLINARY CENTER

Sant'Anna
Scuola Universitaria Superiore Pisa



Number at risk (number of events)

Acoramidis	409 (0)	407 (2)	401 (8)	393 (16)	385 (24)	369 (40)	365 (44)	358 (51)	344 (65)	336 (73)	0 (79)
Placebo	202 (0)	201 (1)	198 (4)	196 (6)	188 (14)	188 (14)	183 (19)	175 (27)	166 (36)	156 (46)	0 (52)

Gillmore JD et al., 2024


Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy

J.D. Gillmore, D.P. Judge, F. Cappelli, M. Fontana, P. Garcia-Pavia, S. Gibbs, M. Grogan, M. Hanna, J. Hoffman, A. Masri, M.S. Maurer, J. Nativi-Nicolau, L. Obici, S.H. Poulsen, F. Rockhold, K.B. Shah, P. Soman, J. Garg, K. Chiswell, H. Xu, X. Cao, T. Lystig, U. Sinha, and J.C. Fox, for the ATTRIBUTE-CM Investigators*



INTERDISCIPLINARY CENTER

Sant'Anna
Scuola Universitaria Superiore Pisa




Subjects Remaining at Risk (Cumulative Events)

Acoramidis	409 (0)	389 (20)	370 (39)	355 (54)	337 (72)	319 (90)	308 (101)	298 (111)	284 (125)	270 (139)	0 (147)
Placebo	202 (0)	191 (11)	172 (30)	159 (43)	152 (50)	143 (59)	135 (67)	129 (73)	121 (81)	108 (94)	0 (102)



Gillmore JD et al., 2024

Changes in NT-proBNP or 6MWT in acoramidis vs. placebo



22.7% of acoramidis-treated patients had clinically meaningful improvement in **NT-proBNP or 6MWD**




Odds ratio: 3.0 (95% CI: 1.8–5.1) $p < 0.0001$





Modified from Cappelli F et al 2025

ATTR drugs: a network meta-analysis

Drug-to-drug
indirect
comparisons




Castiglione V & Vergaro G, submitted





Courtesy of dr. Chubuchnyi

A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells



Aubin Michalon ¹✉, Andreas Hagenbuch¹, Christian Huy¹, Evita Varela ¹, Benoit Combaluzier¹,
Thibaud Damy², Ole B. Suhr ³, Maria J. Saraiva ⁴, Christoph Hock^{1,5}, Roger M. Nitsch^{1,5} & Jan Grimm ¹





Modified from Vergaro et al. 2025

Prediction of Cardiac ATTR Depletion by NI006 Using Mechanistic PK/PD Modeling







Michalon A et al., 2025

ORIGINAL ARTICLE

Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid


Pablo Garcia-Pavia, M.D., Ph.D., Fabian aus dem Siepen, M.D., Erwan Donal, M.D., Ph.D., Olivier Lairez, M.D., Peter van der Meer, M.D., Ph.D., Arnt V. Kristen, M.D., Michele F. Mercuri, M.D., Ph.D., Aubin Michalon, Ph.D., Robert J.A. Frost, M.D., Ph.D., Jan Grimm, Ph.D., Roger M. Nitsch, M.D., Christoph Hock, M.D., Peter C. Kahr, M.D., and Thibaud Damy, M.D., Ph.D.



DEPLE-TTR Phase 3 trial on ALXN2220



INTERDISCIPLINARY
CENTER
Sant'Anna
Scuola Universitaria Superiore Pisa





PRX004 in variant amyloid transthyretin (ATTRv) amyloidosis: results of a phase 1, open-label, dose-escalation study



INTERDISCIPLINARY CENTER

Sant'Anna
Scuola Universitaria Superiore Pisa




Change from baseline in GLS and NIS (B) in patients treated for at least 9 months at doses of 3 mg/kg or higher

CORAMITUG
NNC6019-0001, formerly PRX004




Phase 2, randomized, placebo-controlled trial on NNC6019-0001




Primary endpoints
change from baseline to week 52 in 6MWT and in NT-proBNP levels.

Secondary endpoints
ECV on CMR imaging, GLS, troponin T levels, CVH, reagent visits due to HF

Patients' features and therapeutic decision making



Patients' features and therapeutic decision making



AmyLab

Prof. Giuseppe Vergaro Prof. Michele Emdin



Dr. Alberto Aimò
Dr. Vincenzo Castiglione
Dr. Andrea Barison
Dr.ssa Valentina Spini
Dr. Alberto Giannoni
Dr. Alessandro Valleggi
Dr.ssa Chiara Arzilli
Dr.ssa Roberta Poletti
Dr.ssa Alessandra Gabutti
Inf. Assunta Agazio
Inf. Eleonora Benelli
Sig.ra Silvia Severino, fisiot.

Nuclear Medicine
Dr. Assuero Giorgetti
Dr. Dario Genovesi


Hematology
Prof. Gabriele Buda

Pathology & Mass Spec
Dr.ssa Angela Pucci
Dr. Francesco Greco

Magnetic Resonance
Dr. Chrys Grigoratos
Dr. Giancarlo Todiere

Lab & e Genetics
Dr.ssa Tina Prontera
Dr.ssa Silvia Masotti
Dr.ssa Veronica Musetti
Dr.ssa Nicoletta Botto

Data Manager
Dr.ssa Annalisa Picerni
Dr.ssa Martina Niccolai



amiloidosi@ftgm.it vergaro@ftgm.it